A Glance at Biomarkers of Bone Metabolism
DOI:
https://doi.org/10.3923/pjn.2016.499.504Keywords:
Alkaline phosphatase, osteocalcin, procollagen I peptides, pyridinoline crosslinks, telopeptidesAbstract
The biomarkers of bone metabolism are proteins, which are synthesized by the osteoblast and osteoclast and are released into the bloodstream or circulation as fragments during the formation or degradation of type I collagen. Because some of these fragments are small, they are filtered by the kidney into urine, but the larger fragments which are not filtered are detected in the blood samples. Disorders or disease conditions of skeletal metabolism result in the release of these fragments, which are products of osteoblastic and/or osteoclastic activity. Measurements of these biomarkers of bone metabolism by immunoassay methods show promise as important adjuncts in the early diagnosis of bone changes. These biomarkers are also important in the evaluation and management of skeletal complications of sickle cell disease and other disorders of bone; however they are affected by a variety of physiological and pathological factors. In conclusion, biochemical bone biomarkers are convenient, non-invasive indices of bone metabolic activities, but other analytes such as parathyroid hormone and 25-hydroxycholecalciferol or calcidiol may also be considered.
References
Akesson, K., 1995. Biochemical markers of bone turnover: A review. Acta Orthopaedica Scandinavica, 66: 376-386.
Bolarin, D.M., 2013. Calcium, Phosphate and Magnesium Metabolism. In: Bolarin's Aid to Chemical Pathology, Bolarin, D.M. (Ed.). 2nd Edn., Literamed Publications Nigeria Ltd., Lagos, Nigeria, pp: 501.
Bolarin, D.M., 2006. Review of biochemical bone markers in sickle cell disease. Nigerian J. Orthopaedics Trauma, 4: 1-15.
Bolarin, D.M., 1996. Biochemical Markers for the assessment of skeletal growth in children. Nig. Quart. J. Hosp. Med., 6: 256-261.
Bolarin, D.M., 2013. Bone Disorders. In: Bolarin's Aid to Chemical Pathology, Bolarin, D.M. (Ed.). 2nd Edn., Literamed Publications Nigeria Ltd., Lagos, Nigeria, pp: 633-634.
Bolarin, D.M., 1979. Prolyl hydroxylase and collagen glucosyltransferase in primary hepatocellular carcinoma. Ph.D. Thesis, University of Oxford, England.
Bolarin, M., 1986. Serum enzymes of collagen synthesis and type III procollagen amino-propeptide in Nigerian patients with sickle cell disease. Clin. Chem. Lab. Med., 24: 433-436.
Bolarin, D.M., 2001. Biochemical markers of bone metabolism in sickle cell disease. FMCPath Dissertation, NPMCN.
Bolarin, D.M., P. Swerdlow, A.M. Wallace and L. Littsey, 1998. Type I collagen as a marker of bone metabolism in sickle cell hemoglobinopathies. J. Nat. Med. Assoc., 90: 41-45.
Bolarin, D.M., 2001. Bone-specific alkaline phosphatase protein, total alkaline phosphatase activity and lactate dehydrogenase in sera of patients with sickle cell disease. Haematologia, 31: 51-56.
Bolarin, D. and E. Azinge, 2010. Osteocalcin and specific markers of bone resorption in sickle cell disease. Acta Physiol. Hungarica, 97: 290-296.
Bonnick, S.L. and L. Shulman, 2006. Monitoring osteoporosis therapy: Bone mineral density, bone turnover markers, or both? Am. J. Med., 119: S25-S31.
Compston, J., 2009. Monitoring bone mineral density during antiresorptive treatment for osteoporosis. BMJ, Vol. 338.
Coleman, R., L. Costa, F. Saad, R. Cook and P. Hadji et al., 2011. Consensus on the utility of bone markers in the malignant bone disease setting. Critic. Rev. Oncol./Hematol., 80: 411-432.
De la Piedra, C., A. Rapado, E.D. Diego, M.D. Martin, C. Aguirre, E.L. Gavilanes and M.D. Curiel, 1996. Variable efficacy of bone remodeling biochemical markers in the management of patients with Paget's disease of bone treated with tiludronate. Calcified Tissue Int., 59: 95-99.
Fontana, A. and P.D. Delmas, 2000. Markers of bone turnover in bone metastases. Cancer, 88: 2952-2960.
Ferron, M., E. Hinoi, G. Karsenty and P. Ducy, 2008. Osteocalcin differentially regulates β cell and adipocyte gene expression and affects the development of metabolic diseases in wild-type mice. Proc. Nat. Acad. Sci., 105: 5266-5270.
Garnero, P., E. Sornay-Rendu, B. Claustrat and P.D. Delmas, 2000. Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: The OFELY study. J. Bone Mineral Res., 15: 1526-1536.
Garnero, P., M. Grimaux, P. Seguin and P.D. Delmas, 1994. Characterization of immunoreactive forms of human osteocalcin generated in vivo and in vitro. J. Bone Mineral Res., 9: 255-264.
Hwang, Y.C., I.K. Jeong, K.J. Ahn and H.Y. Chung, 2009. The uncarboxylated form of osteocalcin is associated with improved glucose tolerance and enhanced β-cell function in middle-aged male subjects. Diabetes/Metab. Res. Rev., 25: 768-772.
Kleerekoper, M., 1997. Evaluating and managing osteoporosis. The emerging role of biochemical markers. Clin. Lab. News, 23: 6-7.
Kleerekoper, M., 1997. Biochemical markers: What are they? Proceedings of the 4th International Symposium on Osteoporosis: Research Advances and Clinical Applications, June 4-7, 1997, Washington, DC., pp: 36.
Lipton, A., L. Costa and R.E. Coleman, 2011. Bone turnover markers: Tools for prognosis and monitoring response to bisphosphonates? Breast Dis., 33: 59-69.
Sorva, R., R. Tahtela, M. Turpeinen, K. Juntunen‐Backman and T. Haahtela et al., 1996. Changes in bone markers in children with asthma during inhaled budesonide and nedocromil treatments. Acta Paediatrica, 85: 1176-1180.
Thomas, S.D.C., 2012. Bone turnover markers. Aust. Prescriber, 35: 156-158.
Vasikaran, S., R. Eastell, O. Bruyere, A.J. Foldes and P. Garnero et al., 2011. Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: A need for international reference standards. Osteoporosis Int., 22: 391-420.
Downloads
Published
Issue
Section
License
Copyright (c) 2016 Asian Network for Scientific Information
This work is licensed under a Creative Commons Attribution 4.0 International License.
This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.
